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ABSTRACT 
Clostridium difficile infection (CDI) causes roughly 30,000 deaths each year in the 
United States and the number has been increasing since the early 2000s.  Traditionally, CDI 
is treated with antibiotics (metronidazole or vancomycin).  However, this method is only 
effective in 50% of the patients since it only affects the vegetative C. difficile cells and not 
the spores.  Since the early 2000s fecal microbiota transplants (FMTs) have been used as a 
treatment method, leading to over 80% success rate.  However, FMTs are still considered an 
investigational therapy since the mechanism of how these FMTs treat CDI are unknown.  
This has led to research into probiotics as a possible treatment method.  In this study, the 
objectives were to identify major bacteria species common across 20 FMTs, and investigate 
if some of these bacteria could be potential probiotics.  Our secondary focus was to evaluate 
microorganisms found in kefir, for effectiveness against C. difficile.  Bacteroides and 
Ruminococcaceae were found to be the most prevalent bacteria family across the 20 FMTs.  
Potentially probiotic Lactobacillus and Bifidobacterium only made up roughly 0.2% of the 
bacteria population.  The kefir and the different kefir components (cell-free supernatant, cell 
lysate, fat) inhibition capabilities were tested against C. difficile.  It was found that neither the 
different components nor the entire kefir matrix showed any inhibition against C. difficile. 
However, a Lactobacillus paracasei isolate was found to not only grow alongside C. difficile, 
but to have resistance against the antibiotic vancomycin, making it a potential candidate for 
competitive inhibition against C. difficile.  L. paracasei showed little inhibition when 
inoculated at the same population concentration as the C. difficile and also did not 
significantly inhibit C. difficile growth when used at a higher population. With such studies, 
we will gain a better understanding of the mechanisms of action and potential treatment for 
CDI. 
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CHAPTER 1: GENERAL INTRODUCTION 
 
Clostridium difficile infection (CDI) causes roughly 30,000 deaths each year in the 
United States and the number has been increasing since the early 2000s (Center for Disease 
Control and Prevention; Lessa et al. 2015).  This is partially due to the ability of C. difficile 
to form heat-resistant and antibiotic-resistant spores (Mullany and Roberts 2010), but also 
because of the increase in hyper-virulent strains that have recently started to emerge (Butler 
et al. 2011).  Traditionally, CDI affects mostly elderly patients in hospitals, but there has 
been an increase of CDI cases in younger individuals (Bakken et al. 2011); cases have 
increased to almost 3 CDI cases per 100 hospitalizations in patients under 18 years of age 
(Lessa et al. 2012).  Along with this, about 20% of the cases of CDI are from community-
acquired C. difficile and 35% having CDI symptoms without prior exposure to antibiotics 
(Auclair et al. 2015). 
C. difficile is transmitted though ingestion of the spores.  These spores remain 
metabolically dormant until a favorable environment become present through a disruption in 
the natural gut microbiota (Mullany and Roberts 2010; Vedantam et al. 2012).  When there is 
a disruption of the native bacteria, C. difficile is able to start germinating and producing 
toxins.  These toxins lead to the formation of toxin-mediated diarrhea and 
pseudomembranous colitis, which is known as C. difficile-associated diarrhea (CDAD) 
(Plummer et al. 2004; Mullany and Roberts 2010).  Because C. difficile spores are resistant to 
several antibiotics, they remain in the gut even after treatment; this leads to 15-30% of CDI 
patients having a relapse of CDI, which leads to an increase in mortality and a more chronic 
CDI (Leffler and Lamont 2015).   
2 
 
 
Currently, there are only two main treatment methods used to treat CDI: antibiotics 
and fecal microbiota transplants (FMTs).  Most times, the antibiotics metronidazole or 
vancomycin are used as the first treatment method for patients with CDI.  However, this 
method is only effective in 50% of the patients since it only affects the vegetative C. difficile 
cells and not the spores (Leffler and Lamont 2015).  Along with this, antibiotics further 
disrupt the native microbiota and decrease the overall bacterial diversity, allowing the C. 
difficile spores to germinate after the treatment (Bakken 2014).  With the low success rate 
associated with antibiotics, a new method of treatment for CDI was needed.  Fecal 
microbiota transplants (FMTs) are fecal microbiota obtained from healthy human donors.  
They are thought to help “re-inoculate” the patient’s infected colon with the beneficial 
bacteria (Shankar et al. 2014; Leffler and Lamont 2015).  Studies have shown that FMTs can 
be successful in treating CDI in roughly 90% of patients.  However, since FMTs are still 
considered an experimental procedure, it can be difficult as well as expensive, for patients to 
undergo this treatment method (Bakken 2014).   
Recently, more studies have started to investigate the use of probiotics as a treatment 
method.  Probiotics are known to provide a benefit to the host in several different 
mechanisms, including competitive inhibition, lowing the pH and the production of organic 
acids (Jardine 2009).  Both Lactobacillus and Bifidobacterium have been used in clinical 
trials with CDI patients.  Several studies have shown a decrease in CDAD in patients when 
given a probiotics supplement with antibiotics, with some showing an 80% recovery rate 
without a relapse in CDI (Hickson et al. 2007; Gao et al. 2010; Bakken 2014).  However, 
most of these studies have not investigated the mechanism of the probiotics and overall there 
is not always consistency across the studies (Johnston et al. 2012), thus, leading to an 
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increased need for research into probiotics that specifically help treat CDI and prevent C. 
difficile growth. 
      This thesis focuses on FMTs and their microbiota population to determine which species 
could potentially contributing to the 80% success in treating CDI patients. A second focus of 
the thesis investigates a selection of microorganisms found in kefir, to determine if they 
possess the ability to inhibit C. difficile growth.  The review of literature in the following 
chapter introduces the issues associated with CDI, the current research into FMTs and the 
lack of understanding their mechanism, and the use of probiotics as a treatment method for 
patients with CDI. 
The objective of this research project was to determine the major bacteria species that 
are common across several FMTs that have demonstrated success in treating patients with 
CDI, and investigate if some of these bacteria could be potential probiotics (Lactobacillus & 
Bifidobacterium species). Along with the FMTs, probiotics found in kefir may also have the 
ability to inhibit C. difficile growth either from production of antimicrobial compounds or 
competitive inhibition.  The following hypotheses were tested: 
1) There are bacteria commonalities across FMTs; among them, potential probiotics 
include Lactobacillus and Bifidobacterium bacteria. 
2) The probiotic bacteria present in kefir produce compounds that inhibit Clostridium 
difficile growth. 
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CHAPTER 2: LITERATURE REVIEW 
 
Clostridium difficile Infection 
 Clostridium difficile are toxin-producing, heat-resistant, spore-forming, anaerobic 
bacteria. C. difficile are transmitted through the fecal oral route, from ingesting the spores, 
but it is estimated that 1-3% humans have C. difficile already in their microbiome.  The 
spores that form are metabolically dormant, resistant to both heat and acid, and are highly 
resistant to most standard disinfection methods.  In favorable environments, typically in 
susceptible hosts, C. difficile spores can start to germinate and cause what is known as C. 
difficile infection (CDI) (Vedantam et al. 2012).  In an individual with a healthy gut 
microbiota, the risk of CDI developing is low (Butler et al. 2011).  However, this risk 
increases when a patient becomes susceptible due to a disturbance to their gut microbiota 
from antimicrobials or other illnesses (Mullany and Roberts 2010).  Other factors also 
Figure 2.1.  CDI pathogenesis in humans. (Adapted from Seekatz and Young 2014) 
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increase the risk of CDI development, such as the host immunity, gender, age or 
gastrointestinal procedures (Butler et al. 2011). 
      In healthy patients, normal microbiota produce short-chain fatty acids and lactic acid due 
to breaking down the non-absorbable carbohydrates; this leads to a decrease in pH, which 
can prevent pathogens from germinating.  A healthy microbiota also prevents pathogenic 
bacteria from growing due to colonization resistance, which includes competitive exclusion. 
With a disruption of these microbiota in the colon, they can no longer break down the present 
carbohydrates and the microbiota population decreases, allowing for a pathogen such as C. 
difficile to germinate.  Germination of C. difficile also requires the bile salt, taurocholate, and 
glycine, is which are naturally present; these two components must be present to trigger the 
spore to start germinating. When C. difficile starts to colonize the colon, it starts to produce 
two exotoxins: TcdA, the primary enterotoxin and TcdB, a cytotoxin (Plummer et al. 2004).  
These two toxins causes inflammation in the colon, which leads to tissue damage and further 
disrupts the normal microflora (Vedantam et al. 2012).  Overall, they lead to the symptoms 
known as toxin-mediated diarrhea and pseudomembranous colitis (Mullany and Roberts 
2010).  Together, this is classified as C. difficile-associated diarrhea (CDAD) (Johnston et al. 
2012) in patients with C. difficile.   
      The biggest threat for patients with CDI, is when it becomes recurrent.  Recurrent CDI 
happens in 15-30% of patients after the initial bout of CDI.  When CDI is recurring, it can 
become more chronic and unresponsive to treatments, which can lead to an increase death 
risk (Bakken et al. 2011). Recurring CDI happens due to spores that are still present in the 
gut even after antibiotic treatment, an impaired immune response to the infection and a 
weakened barrier function of the colonic microbiota (Leffler and Lamont 2015). 
6 
 
 
      According to the Centers for Disease Control and Prevention (CDC) roughly 30,000 
individuals died in the United States due to CDI in 2011 (Center for Disease Control and 
Prevention; Lessa et al. 2015). Unfortunately, this number of deaths has increased over the 
last few years due to emergence of hyper-virulent and antibiotic-resistant strains of C. 
difficile.  Traditionally, C. difficile affects older individuals in a hospital or those exposed to 
antibiotic treatments.  About 90% of the deaths due to C. difficile are in patients 65 years or 
older, making it the 18th leading cause of death of this age division (Lessa et al. 2012; Evans 
and Safdar 2015). However, there has been an increase of CDI in young, healthy individuals 
who acquire C. difficile from the environment (Bakken et al. 2011).  In a study by Lessa et al. 
(2012), it was found that there has been a substantial increase in CDI in individuals under the 
age of 18; cases have increased from 0.7 per 1000 hospitalizations in 1997 to 1.28 per 1000 
Figure 2.2. Incidences of C. difficile infection per 1000 
hospitalizations by age. Abbreviation: CDI, C. difficile infection 
(Adapted from Lessa et al. 2012) 
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hospitalizations in  2006 (Figure 2.2).  This is believed to be due to the increase in 
community acquired C. difficile and the emergence of the hyper-virulent strains.  About 20-
28% of all the CDI cases are from community acquired C. difficile and around 35% of these 
patients form CDI without exposure to an antibiotic (Auclair et al. 2015).  The hyper-virulent 
strains that have been emerging since the early 2000s have an increase in toxin production, 
including a new binary toxin, have increased sporulation, which increases its ability to 
spread, and high levels of resistance to some antibiotics (Butler et al. 2011).  It was shown in 
a study by (Lessa et al. 2012), that the amount of C. difficile infections in the US from 2000 
to 2014 increased in several age groups; with it more severely in the older age groups (shown 
in Figure 2.3).  Our understanding of C. difficile and CDI is continuing to improve, but with 
the emerging new strains and an increase in community acquired C. difficile, CDI has 
Figure 2.3 Discharge rate for Clostridium difficile infection from US 
short-stay hospitals by age (Lessa et al. 2012) 
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become one of the more important health-care associated pathogens.  Thus, leading to the 
need for increased research into current and alternative treatment methods. 
 
Current Treatments for Clostridium difficile Infection: Antibiotics and Fecal 
Microbiota Transplants 
 
 Currently, there are two main methods used to treat CDI: antibiotics and fecal 
microbiota transplants (FMTs).  Traditionally, antibiotics are used as the first treatment 
method for patients with CDI.  The primary antibiotics used are metronidazole and 
vancomycin.  However, it is found that antibiotics are only successful in 50% of patients with 
recurring CDI (Leffler and Lamont 2015).  Antibiotics are used to treat patients with CDI 
because they can potentially reduce the germinated C. difficile strains, however, vancomycin 
and metronidazole further disrupt the microbiota in the intestinal tract, which then allows the 
C. difficile spores, which are resistant to the antibiotics, to germinate; thus, leading to 
recurring CDI (Bakken 2014; Leffler and Lamont 2015).  The interaction of antibiotics for 
CDI patients have been described as a three phase system by Louie et al. (2015).  The first 
phase is the introduction of the antibiotics to the intestinal microbiota, which impairs the 
native microbiota and leads to an overgrowth of C. difficile. The second phase is the 
production of toxins and inflammation, which further disrupts the native microbiota, leading 
to the onset of diarrhea. Lastly, there is the struggle between the native microbiota trying to 
reestablish themselves in both diversity and quantity, but must try to outgrow the C. difficile 
that have established themselves.  With increased use of antibiotics has been the emergence 
and spread of C. difficile strains that are resistant to both metronidazole and vancomycin.  
This resistance is caused when increased use provides antimicrobial selection pressure 
through either mutation of new resistance genes or alteration of the bacterial ecology (i.e. 
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transfer of naturally occurring resistances from one strain to another) (Heywood and Netts 
1993).  Since the recent emergence of some antibiotics-resistant C. difficile strains, and due 
to antibiotics’ low success rate, FMTs have started to become an alternative treatment 
method for CDI. 
      As stated before, the colonic microbiota, which provide colonization resistance against 
pathogens, are thought to be the main way to prevent CDI (Leffler and Lamont 2015).  When 
a patient has CDI, she or he also has a decrease in the normal gut microbiota, which leads to 
the infection and potential recurring CDI.  Fecal Microbiota Transplants (FMTs) are fecal 
microbiota obtained from a healthy human donor that are utilized to treat patients who have 
recurrent CDI.  Each fecal donation is put through a rigorous screening process to look for 
several pathogens or viruses (Bakken et al. 2011; Shankar et al. 2014).  It is thought that 
through the FMT, the patient’s infected colon gets “re-inoculated” with beneficial 
microbiota.  This then leads to an increase in their growth and reestablishing the colonization 
resistance against C. difficile.  FMTs have been successful in treating roughly 90% of 
patients with CDI (Leffler and Lamont 2015). In a study done by Patel et al. (2013), 31 
patients were administered FMTs to investigate the effectiveness for treating CDI as well as 
identifying any side-effects from the procedure. Prior to the FMT, all the patients suffered 
Table 2.1 Fecal Microbiota Transplantation Primary Outcomes (Adapted from Patel et al. 2013) 
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from CDAD, 81% had abdominal pain, and 90% suffered from fatigue. After the treatment, 
patients were evaluated on their improvement or resolution of these symptoms.  In Table 2.1, 
it shows the improvement or resolution of each symptom after FMT procedure.  Overall, the 
majority of the patients had some type of resolution or improvement of diarrhea and 
abdominal pain. Only 3 out of the 31 patients had a recurring CDI (81% recovery rate).  In a 
similar study from van Nood et al. (2013), shown in Figure 2.4, 13 out of 16 patients (81%) 
were cured after the first FMT infusion, and 2 out of 16 after the second infusion; resulting in 
a 94% cure rate through FMTs.  With antibiotics alone, only 31% (4 out of 13) of the patients 
were cured using only vancomycin and 23% (3 out of 13) cured using vancomycin and a 
bowel lavage.  These findings support the statement that FMTs have a significant higher 
success rate compared to antibiotics.   
Figure 2.4. Rates of Cure without Relapse for Recurrent 
Clostridium difficile Infection.  (Adapted from van Nood et 
al. 2013) 
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       As stated before, the success rate from FMTs are thought to be related to increasing the 
patients’ native gut microbiota diversity. During CDI, the patients have a shift in their gut 
microbiota.  In one study by van Nood et al. (2013), they found that patients with CDI had 
low overall gut diversity compared to a healthy individual.  This study also investigated how 
the diversity changed from before to after the FMT infusion.  Figure 2.5 shows how patients’ 
gut microbiota diversity changed before and after the infusion of the FMTs; it shows that 
after the FMT, there was an increase in the diversity so that it starts to resemble that of the 
healthy donors’.  It is well documented that in a healthy human gut, Bacteroidetes and 
Firmicutes are the two most dominate bacterial divisions (Khoruts et al. 2010) and that both 
of these decrease in patients with CDI (Khoruts et al. 2010; Louie et al. 2015).  Similarly, in 
a study by Shankar et al. (2014), low diversity of intestinal microbiota was found in CDI 
patients compared to the healthy donors and after the FMT infusion, the CDI patients had 
both an increase in diversity but also had similar microbiota population of the donor.  This 
Figure 2.5.  Microbiota Diversity in Patients before 
and after Infusion of Donor Feces, as Compared 
with Diversity in Healthy Donors (Adapted from 
van Nood et al. 2013) 
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microbiota community of the CDI patients’ was monitored over a four month period and it 
was found that the CDI patients continued to have high microbiota diversity of that of the 
donors’ FMT (Shankar et al. 2014), supporting that the FMTs are possibly “re-inoculating” 
the patients’ intestinal tracts.  However, the key mechanism, or bacteria from the FMTs that 
the patients benefited the most from, are still unknown (Schenck et al. 2015). 
      Even though FMTs have been shown to be very successful, there are still some 
downsides to this procedure.  FMTs are considered to be an investigational therapy or used as 
a “last resort” therapy; therefore some third party payers and medical services have been 
unwilling to pay for the procedure. Along with this, there is a lack of access to health care 
centers that can perform FTMs.  This leads to patients having to pay more out of pocket or 
finding alternative treatment methods, hence other treatment methods for CDI are needed 
(Patel et al. 2013; Bakken 2014). 
Probiotics as a Treatment Method for Clostridium difficile Infection 
 
In the digestive tract in humans there are several main microbiota genera; these are 
Bacteroides, Enterococci, Lactobacillus and Bifidobacterium (Jardine 2009).  Many factors, 
such as illness, age, and use of antibiotics, can affect the diversity and genera of bacteria 
present.  As stated before, patients with CDI have a change in their gut microbiota; the 
Bacteroides and Firmicutes start to decrease, along with an overall decrease in the diversity 
of bacteria species. Through FMTs it is thought to help reintroduce the native gut bacteria, 
but FMTs are not always an option, thus, additional treatment methods are need (Patel et al. 
2013; Bakken 2014).  Probiotics as a treatment for patients with CDI, is one area that is 
starting to be investigated. Probiotics are defined as “live microorganisms that when ingested 
by in adequate amounts, confer a health benefit on the host” (World Health Organization and 
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Food and Agriculture Organization of the United Nations 2002).  There have been several 
genera of bacteria that have been identified as probiotic bacteria; the primary genera being 
Lactobacillus and Bifidobacterium.  Each specific potential probiotic bacteria strain must go 
through a complex process, using genetic and phenotypic techniques, to establish the 
identity, type and classification of the probiotic.  In addition to this, the bacteria must 
undergo a functional aspect and safety assessment to determine its probiotic functional 
mechanisms as well as determine if the bacteria has “General Recognized As Safe” (GRAS) 
status, which is set by the American Food and Drug Association (FDA).  Each probiotic 
strain must have a documented health effect and be clinically validated  (Lee & Salaminien 
Figure 2.6.  Probiotic Prevention Strategy against CDI. (Adapted from Spinler 
et al. 2016).  Disruption of a healthy GI microbiota by antibiotics increases 
CDI susceptibility.  Adjunctive probiotic therapy provides protection against 
CDI by stabilizing the GI microbiota protecting the host by various 
mechanisms and preventing C. difficile invasion.  
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2009; Kneifel et al. 2010).  There are many different probiotic functional mechanisms needed 
to be considered a probiotic, some of which provide health benefits and these different 
mechanisms are important to know, since the help establish a potential bacteria as a 
probiotic.  To start, probiotics need to be able to withstand the passage from consumption to 
intestine and then must be able to then survive in the human GI track.  Therefore, the bacteria 
must be resistant to gastric conditions (i.e. bile and acids) as well as adherence to mucus and 
human epithelial cells (Lee & Salaminien 2009).  Some known probiotics also have functions 
to help decrease or prevent the growth of pathogenic bacteria; they do this through several 
different mechanisms.  One is by the production of different organic acids and gut protective 
metabolites (short-chain fatty acids, acetate, lactic acid, diacetyl, hydrogen peroxide), which 
help in lowering the pH of the gut environment and strengthens the gut barrier function, to 
create an environment that pathogenic bacteria cannot survive in (Jardine 2009; Lee & 
Salaminien 2009; Spinler et al. 2016).  Probiotic bacteria can also produce different 
antimicrobials such as bacteriocins.  These bacteriocins are protein groups that can interfere 
with enzymatic reactions, bacterial membranes, and effect the transcription, translation and 
replication of many pathogenic bacteria (Fijan 2016; Tenea and Yépez 2016). The other 
mechanism for preventing pathogenic growth is through competitive inhibition (competitive 
exclusion).  Competitive inhibition can be driven by competing for bacterial adhesion sites in 
the intestinal epithelial surface or competing for a similar nutrient source.  Many probiotics 
are able to out compete pathogens just by having a higher population number, using 
coaggregation mechanisms (bacteria to bacteria interactions) and by regulation the intestinal 
motility and mucus secretion. In addition, probiotics may also utilizing some of the other 
probiotic functional mechanisms to increase their competitive inhibition advantage over 
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intruding pathogens (Liong 2011; Ötleş 2014).  Some other mechanisms are stimulating the 
immune system, and binding and metabolizing toxic substances (Jardine 2009; Lee & 
Salaminien 2009; Fijan 2016; Tenea and Yépez 2016; Spinler et al. 2016).   
Two main probiotic genera present in healthy humans are Lactobacillus and 
Bifidobacterium.  In some studies, it has been shown that with illness and age, the 
Bifidobacterium start to decrease in the gut (Jardine 2009).  However, in a study done by 
Louie et al. (2015), many of the Bifidobacterium and Lactobacillus species remained 
prevalent in the gut even after treatment with both vancomycin and fidaxomicin.  This 
suggests that, potentially, these types of probiotics could be utilized in CDI patients since 
they seem to be able to survive and have some resistance to the antibiotics used.  Plummer et 
al. (2004) suggests that probiotics therapy (Biotherapy) acts similarly to FMTs in that their 
role is to restore the colonization resistance of the gut microbiota, , through several of the 
probiotic functional aspects, that was disrupted during antibiotic treatment to help prevent 
recurrent CDI or even the initial onset of CDI.  In this study, Plummer found that there was a 
4% decrease in C. difficile in the fecal sample of the patients in the probiotic group compared 
to the placebo as well, as a decrease in the toxins from C. difficile (Plummer et al. 2004).  
This suggests that the probiotics may have an impact in both prevention of C. difficile spread 
but also with keeping the present C. difficile in an asymptomatic carrier state, meaning in 
spore form.   
Similarly, two clinical studies focused on treating CDI patients with probiotics to 
prevent recurrent CDI along with an antibiotic treatment.  The study done by Gao et al. 
(2010) used a probiotic capsule containing Lactobacillus acidophilus and Lactobacillus 
casei.  In this study, there were three groups: placebo, probiotic group 1 (given 1 capsules) 
16 
 
 
and probiotic group 2 (given 2 capsules).  Gao and colleagues found that there was a 
decrease in CDAD in both the probiotic groups compared to the control; 28% of the placebo 
group tested positive for CDAD while only 9% in probiotic group 1 and 1% in probiotic 
group 2.  In the second study, Hickson et al. (2007) looked at a probiotic yogurt drink, 
Actimel, that contained Lactobacillus casei, L. bulgaricus and Streptococcus thermophilus.  
The Actimel was found to decrease CDAD compared to those in the control by 17% and no 
C. difficile toxins were found in the probiotic group compared to 52% of the control group 
testing positive for toxins.   
Another study, done by Bakken (2014), took a slightly different approach; they 
looked at using kefir, a fermented milk beverage, as the probiotic supplement with a 
staggered and tapered antibiotic withdraw (STAW).  STAW simply means that the dose of 
antibiotics is decreased over time. Kefir was chosen as a probiotic supplement due to its 
diverse collection of probiotics strains (Bakken 2014).  This method was used because it is 
postulated that the STAW allows the C. difficile spores time to start germinating, between the 
drug-free periods so that the majority of C. difficile (vegetative cells and spores) are removed 
from the patient and the kefir would help enrich and increase diversity of the native 
microbiota that are affected by the antibiotics.  In this study, Bakken focused on recurrent 
CDI, having each patient act as their own control, since they had several rounds (between 2-9 
relapses) of CDI that were not cured with antibiotics alone.  The kefir supplement along with 
the STAW displayed an 84% (21 out of 25 patients) effectiveness of treating CDI.  Even 
after a 9-month follow up, only 4 of the 25 patients had a relapse of CDI.  Of the 21 patients 
with a successful treatment, all had reestablished normal bowel functions and 20 remained 
symptom-free after 12 months.  This study shows that the use of probiotics could be as 
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successful in treating CDI as FMTs, however, the authors did not investigate which of the 
probiotics in the kefir were contributing to the 84% success. 
In a meta-analyses from Johnston et al. (2012), of several clinical studies (including 
the from Gao et al & Hickson et al.), probiotics tended to be favored over the control when 
used to treat CDAD.  However, most of these studies focused on CDAD and if the probiotics 
supplement decrease CDAD.  They did not look into specifically which of the probiotic 
strains were providing the increased treatment success.  Johnston et al. (2012) also showed 
that even though there is a positive trend for probiotics, the results are not always consistent 
across the studies.  This just goes to show that more research is needed in this area as well as 
more investigation into the specific probiotic strains that contribute to the decrease of CDI 
and the prevention of C. difficile growth. 
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CHAPTER 3: IDENTIFYING COMMONALITIES OF BACTERIA FOUND IN 
FECAL MICROBIOTA TRANSPLANTS 
 
ABSTRACT 
In this study, the objective was to identify major bacteria species common across 20 
fecal microbiota transplants (FMTs) that are used to treat Clostridium difficile infection 
(CDI), and investigate if some of these bacteria could be potential probiotics.  CDI is 
traditionally treated with antibiotics (metronidazole or vancomycin).  However, this method 
is only effective in 50% of the patients since it only affects the vegetative C. difficile cells 
and not the spores.  Since the early 2000s fecal microbiota transplants (FMTs) have become a 
popular treatment method for CDI patients, leading to over 80% success rate.  However, 
FMTs are still considered an investigational therapy since the mechanism of how these FMTs 
treat CDI are unknown.  It was hypothesis that there are bacteria commonalities across 
FMTs; among them, potential probiotics include Lactobacillus and Bifidobacterium bacteria. 
Bacteroides and Ruminococcaceae were found to be the most prevalent bacteria family 
across the 20 FMTs.  Faecalibacterium prausnitzii was one the most prevalent species 
present across all the FMTs, making about 15% of the gut microbiota.  The probiotic 
Lactobacillus and Bifidobacterium only made up roughly 0.2% of the bacteria population. 
 
INTRODUCTION 
 
A diverse commensal microbiota of humans has been well documented as being 
crucial in maintaining health.  Several disease have been associated with a dysbiosis in the 
gut microbiota; one of these is Clostridium difficile infection (CDI) (Ranjan et al. 2016).  
CDI is typically associated with hospitals and older adults (65 years and older) caused from 
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the spread of C. difficile spores. CDI has caused roughly 30,000 deaths in the US and has 
been increasing due to hyper-virulent and antibiotic C. difficile strains  (Center for Disease 
Control and Prevention; Lessa et al. 2012; Evans and Safdar 2015).  The biggest risk for CDI 
patients is when the infection becomes recurrent; this happens in 15-30% of CDI patients.  
When CDI become recurrent, it becomes more difficult to treat and can lead to an increase 
risk for death.  Recurrent CDI happens due to spores, which are resistant to the antibiotics, 
that remain in the gut and can start germinating after treatment causing several bouts of 
infection (Bakken et al. 2011; Leffler and Lamont 2015). 
 Currently the two main treatment methods for CDI are through antibiotics or fecal 
microbiota transplants (FMTs).  However, antibiotics have a low success rate, roughly 50% 
compared to FMTs, which have around 80% success (Leffler and Lamont 2015).  It is 
postulated that FMTs work in treating CDI by re-inoculating the intestinal tract to re-
establish normal bowel function (Bakken et al. 2011).  But even with FMTs’ high success 
with treating CDI, there is still a sense of reluctance to fully utilize this procedure.  FMTs are 
still considered an investigational therapy since the mechanism of how FMTs work to treat 
CDI are unknown, along with many of the risks involved (Patel et al. 2013).  Because of this, 
many patients are forced to pay for FMTs out of pocket or seek out other treatment methods.  
This increases the need for further research into the type of microbiota present in FMTs as 
well as establishing what bacteria population make up a healthy microbiota. 
Metagenomic sequencing, such as whole genome shotgun sequencing (WGS) and 16s 
rRNA, is a valuable tool in determining and analyzing complex microbial communities.  It is 
through these sequencing techniques that many of the human gut microbiota influences, such 
as on health and physiology, have been established (Qin et al. 2010). WGS and 16s rRNA are 
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essential for identifying and enumerating the bacterial species that are represented in the gut 
along with identifying some of their complex interactions between bacteria species and 
bacteria and the host.  Sequencing has enabled determining the major bacteria phyla found in 
the gut, such as the Bacteroidetes and Firmicutes, which are known to represent the majority 
of human gut microbiota.  Compared to the more modern sequencing, 16s rRNA, WGS can 
more clearly define the taxa present, down to the species level (Ranjan et al. 2016).  One of 
the biggest challenges with FMTs is that the bacteria community and diversity varies from 
donor to donor, so to identify the major commonalities across several FMTs may start to help 
identify the crucial microbiota needed to establish a healthy microbiota. 
The purpose of this study was to start identifying the bacterial commonalities across 
several FMTs that have been used successfully to treat CDI as well as determine if some of 
these common bacteria are Lactobacillus and Bifidobacterium species that are common to 
dairy products. 
MATERIALS AND METHODS 
Sample acquisition 
Although stool was acquired from healthy donors, and stored at OpenBiome 
(Somerville, MA) stool bank, human subjects’ research paperwork was filed with the ISU 
Institutional Review Board prior to acquisition of any stool samples.  Twenty different fecal 
samples, from 20 different healthy individuals who were approved donors, were acquired 
from OpenBiome’s frozen storage. 
DNA extraction, amplicon preparation, pyrosequencing, and data analysis 
Genomic DNA from bacteria in stool was purified using the The PowerSoil® DNA 
Isolation Kit (MO BIO Laboratories, Inc. Carlsbad, CA). DNA preparations were quantified 
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using Quan-iT™  PicoGreenH dsDNA Kit (Invitrogen, Carlsbad, CA, USA) and a Nanodrop 
3300 Fluorospectrometer (Thermo Fisher Scientific, Wilmington, DE). Each genomic DNA 
sample was subjected to whole genome DNA amplification (Illustra™ GenomiPhi™ V2 
DNA Amplification Kit, GE Health Sciences, Piscataway, NJ) following the manufacturer’s 
standard protocol. The resulting DNA was purified using ethanol-precipitation and 
resuspended in Qiagen AE elution buffer.  These were quantified using a Nanodrop 1000 
Spectrophotometer (Thermo Fisher Scientific, Wilmington, DE). The resulting products were 
used as templates for both Shut-gun Whole Genome (Ranjan et al. 2016) and 16s rRNA 
libraries, conducted at Argonne National Laboratory (Chicago, IL). The sizes of all PCR 
products were confirmed by agarose gel electrophoresis on 1% SB buffer gels (Faster Better 
Media LLC, Hunt Valley, MD). The quality of the 16S rDNA amplicon libraries were tested 
by running them, under the supervision of collaborator Phillips, on a 2100 Agilent 
bioanalyzer on a DNA High Sensitivity chip (Iowa State University DNA Facility, Ames, 
IA).  
Characterization of bacteria 
Sequence handling and analysis for determination of operational taxonomic units 
(OTUs) was determined using MG-RAST pipeline (Glass et al. 2010) for the WGS and the 
QIIME program (Caporaso et al. 2010) for the 16s rRNA sequences, following the standard 
procedure methods. The WGS sequences were compared with the GenBank database 
analysis program through MG-RAST using the analysis program on MG-RAST.  The 
frequency of bacteria in each phylum, class, order, family and genus were determined and 
classified.  Due to backlogs with the MG-RAST pipeline, only 19 of the 20 FMTs WGS were 
analyzed through the MG-RAST pipeline. 
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RESULTS AND DISCUSSION 
Through both 16s RNA and WGS, it was determined that the main bacteria phyla 
across the FMTs were Bacteroidetes and Firmicutes, making up 37% and 55% of the gut 
microbiota, respectively (Figure 3.1 & Figure 3.2).  This was expected, since these two phyla 
have been well established as the main human gut microbiota (Eckburg et al. 2005; Heinken 
et al. 2014).  Of the Bacteroidetes, 34% were made up of the genus Bacteroides (family: 
Bacteriodacea), which was the largest population in the fecal samples (Figure 3.3).  
However, no one Bacteroides species could be identified as a major commonality across the 
FMTs; meaning there was very high diversity of Bacteroides in the gut microbiota.  Twenty 
different Bacteroides species were found to be common across the FMTs, Bacteroides 
vulgatus (5% of bacteria in FMTs) being the most prevalent (Table 3.1).  This is similar to 
the findings by Bakken et al. (2011) and Khoruts et al. (2010), with B. vulgatus being the 
primary Bacteriodacea in the FMTs as well as in the CDI patients after an FMT infusion.   
Unfortunately, many of the Bacteroides species, including B. vulgatus, do not have 
defined host interactions and it is still unknown if they provide any beneficial capabilities for 
the human host.  Some of these could potentially be probiotics but would have to go through 
the process, mentioned in Chapter 2, to be established as probiotic.  However, studies show 
mixed reviews on whether Bacteroides species provide any benefits; Cuív and others (2011) 
state that many studies show B. vulgatus both capable of promoting and protecting against 
colitis and can be considered an opportunistic pathogen. One hypothesis is, that in the correct 
concentration, B. vulgatus could be beneficial, but with too high of a population, could cause 
complications.  Identifying its mechanism in the gut environment would be crucial in 
establishing if it is beneficial with treating CDI.  Nevertheless, knowing that these 20 species 
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make up most of the human Bacteroides may provide better guidelines for selection of 
potential beneficial bacteria in treating CDI.   
Over 22% of the population of the FMTs was composed of the family 
Ruminococcaceae (Phylum: Firmicutes).  Unlike the Bacteroides species, one major species 
was identified across each FMT; Faecalibacterium prausnitzii made up 15% of the 
microbiota bacteria and 25% of the overall Firmicutes species.  It is generally accepted that 
F. prausnitzii makes up 5-15% of healthy human microbiota (Hold et al. 2003; Miquel et al. 
2013).  Unlike many of the Bacteroides species, F. prausnitzii is known to provide some 
benefits to the host.  In studies by both Hold et al. (2003) and Khan et al. (2014), they found 
that F. prausnitzii is a major butyrate-producer and also produces anti-inflammatory 
compounds.  Butyrate is one of several short-chain fatty acids (SCFA) that are known to play 
an important role in providing protection against cancer and ulcerative colitis.  Several 
studies have shown that with disease, there is a shift in the gut microbiota (Clemente et al. 
2012).  Miquel et al. (2013) determined that with many diseases, such as inflammatory bowel 
syndrome (IBS) or ulcerative colitis (UC), there is a decrease in F. prausnitzii, and F. 
prausnitzii can potential help treat IBS patients.  However, it has not been well documented 
if F. prausnitzii decreases in CDI patients.  Although F. prausnitzii is not fully established as 
a probiotic, due to its high oxygen sensitivity (Miquel et al. 2013), it could be an important 
beneficial bacteria for treating CDI patients. 
Originally, the hope was that there would be a large concentration of lactic acid-
producing bacteria (Lactobacillus) and other known probiotic bacteria (Bifidobacterium) in 
the FMTs since these were the probiotic bacteria used in other clinical studies (Hickson et al. 
2007; Gao et al. 2010; Bakken 2014).  Many species of these bacteria are considered 
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probiotic because they have established benefits for human health and have documented 
inhibition capabilities for other pathogenic bacteria (Jardine 2009; Lee & Salaminien 2009).  
However, it was found from the WGS data that Lactobacillus and Bifidobacterium only made 
up an average of 0.19% and 0.17% of the bacterial population across the 20 fecal samples, 
ranging in each FMT from 0.01% to 1% (Figure 3.4), respectively.  Even though these two 
probiotic genera are only present in small concentration, their benefits are well established, 
as mentioned in Chapter 1, and many are already being investigated as potential probiotics to 
use to treat patients with CDI.  Therefore, knowing which species are most common across 
the FMTs could be a valuable tool in creating a probiotic supplement to treat CDI patients.   
The WGS identified a large diversity of Lactobacillus species.  There were 34 
different Lactobacillus species present across the 19 FMTs (Table 3.3), with around 17 of 
them being present in all 19 in larger percentages (greater than 0.003% of total FMT 
microbiota and greater than 1% of Lactobacillus total population).  Lactobacillus delbrueckii 
(L. delbrueckii subsp bulgaricus) was found to be the most prevalent, making up 12% of the 
Lactobacillus species.  L. delbrueckii subsp bulgaricus is one of the two bacteria required for 
yogurt to be called yogurt.  A study by Hickson et al. (2007) utilized L. delbrueckii with 
several other probiotics in a probiotic yogurt drink, Actimel, and found that it significantly 
decreased C. difficile-associated diarrhea (CDAD).  Along with L. delbrueckii, L. salivarius, 
L. paracasei, L. plantarum, and L. reuteri were also common across the FMT samples, 
making up 10%, 8%, 8% and 7% of the Lactobacillus population, respectively.  Similar to L. 
delbrueckii, these species are found in fermented dairy products, and have also been utilized 
in studies to treat CDI patients and are known to help treat antibiotic-associated diarrhea 
(AAD) or acute pediatric diarrhea (McFarland 2015).  In a study by Ambalam et al. (2015), 
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L. paracasei was found to inhibit C. difficile in competitive inhibition tests.  L. casei and L. 
acidophilus are two other main probiotics that have been utilized in CDI treatments since 
they are known to help improve normal microbiota and also help with AAD.  They were 
found to make up only 3% of the Lactobacillus species in the present study.   
Unlike the Lactobacillus species, the Bifidobacterium species had less diversity.  The 
WGS identified 13 different Bifidobacterium species across the 19 FMTs (Table 3.4), with 
11 being present in all 19 samples (in populations greater than 0.003% of total FMT bacteria, 
greater than 1% of Bifidobacterium total population).  Bifidobacterium longum made up an 
average of 50% of the total Bifidobacterium population across the 19 FMTs.  B. animalis 
(Bifidobacterium animalis subsp. lactis) and B. bifidum made up 14% and 11% of the 
Bifidobacterium population.  These species, much like many of the Lactobacillus ones, are 
commonly found in fermented dairy products and have also be used in CDI studies.  In a 
study by (Kondepudi et al. 2012), they found that B. longum exhibited high antimicrobial 
activity against C. difficile, making it possibly one important probiotic needed to treat CDI.  
B. bifidum is known to help displace pathogenic bacteria and has been utilized with other 
probiotics in CDI clinical trials (Johnston et al. 2012; McFarland 2015).  B. animalis is 
known to improve normal microbiota as well as showed the ability to inhibit C. difficile in a 
study by Schoster et al. (2013).  Much like with Lactobacillus, knowing the major 
Bifidobacterium present could help with narrowing in on the crucial probiotics to consider 
for food-based treatment or prevention of CDI.   
Both Lactobacillus and Bifidobacterium species were identified in the WGS, and the 
major bacteria species for each genera were also identified. Figure 3.5 displays which 
Lactobacillus species could potentially make up a food-based cocktail, based on the results 
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from the WGS of the 19 FMTs.  Knowing the major commonalities of probiotics naturally 
found in healthy human microbiota donors may help with identifying the “ideal” probiotic 
culture for treating or preventing CDI. 
 
CONCLUSION 
Overall, Bacteroidetes and Firmicutes phyla made up the largest population across all 
19 FMTs, suggesting that these bacteria may play an important role in inhibition, prevention 
or treatment of C. difficile.  However, many of these species are not fully understood 
regarding how they help benefit gut microbiota.  Faecalibacterium prausnitzii was one the 
most prevalent species present across all the FMTs and is known to provide the host with 
butyrate and anti-inflammatory compounds; it has been used to treat IBS. Even though the 
Lactobacillus and Bifidobacterium species only made up a small percentage of the FMTs, 
knowing the main species and their population that are present in the gut could lead to 
creating a probiotic cocktail that more specifically mimics that of healthy human adults.  
Knowing how the Lactobacillus and Bifidobacterium species work together may help 
establish a better understanding of how to utilize them in treating CDI patients.  As 
technologies improve in the area of culturing and genomic sequencing, more understanding 
of how the gut microbiota function, may be further understood. 
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Figure 3.1. Main bacteria phylum identified through 16s rRNA sequencing across 20 fecal microbiota transplants.  1-19 
represent the different FMTs
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Figure 3.2. Main bacteria phylum identified through whole genome shotgun sequencing across 19 fecal microbiota 
transplants.  1-19 representing the different FMTs
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Figure 3.3. Main bacteria family groups identified through 16s rRNA across 19 fecal microbiota transplants. 1-19 representing 
the different FMTs
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   Table 3.1.  Average frequency of most prevalent Bacteroides species found in 19 fecal 
microbiota transplants 
   
  
FAMILY SPECIES AVERAGE 
PERCENT IN FMTS 
BACTERIODACEA 
Bacteroides vulgatus 5.06% 
Bacteroides eggerthii 4.30% 
Bacteroides dorei 3.91% 
Bacteroides stercoris 3.13% 
Bacteroides uniformis 3.1% 
Bacteroides helcogenes 2.96% 
Bacteroides ovatus 1.71% 
Bacteroides cellulosilyticus 1.19% 
Bacteroides intestinalis 1.15% 
Bacteroides thetaiotaomicron 0.98% 
Bacteroides fragilis 0.86% 
Bacteroides finegoldii 0.76% 
Bacteroides xylanisolvens 0.62% 
Bacteroides pectinophilus 0.60% 
Bacteroides caccae 0.40% 
Bacteroides coprocola 0.39% 
Bacteroides capillosus 0.36% 
Bacteroides plebeius 0.34% 
Bacteroides coprophilus 0.34% 
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Table 3.2. Average frequency of Ruminococcaceae species found across 19 fecal 
microbiota transplants 
  
FAMILY 
SPECIES AVERAGE 
PERCENT IN 
FMTS 
RUMINOCOCCACEAE 
Faecalibacterium prausnitzii 14.99% 
Subdoligranulum variabile 0.57% 
Anaerotruncus colihominis 0.56% 
Ruminococcus gnavus 0.28% 
Ruminococcus obeum 0.23% 
Ruminococcus albus 0.12% 
Ruminococcus torques 0.10% 
Ethanoligenens harbinense 0.06% 
Ruminococcus lactaris 0.06% 
Acetivibrio cellulolyticus 0.03% 
  
 
Figure 3.4. Percent of Lactobacillus & Bifidobacterium species found across 19 fecal transplant materials. 1-19 representing the 
different FMTs.
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Table 3.3 Average frequency of each Lactobacillus species out of the total Lactobacillus 
genus found in the 19 fecal microbiota transplants. 
SPECIES 
PERCENT  OF 
SPECIES IN 
LACTOBACILLUS 
GROUP 
L. delbrueckii 12.16% 
L. salivarius 9.84% 
L. paracasei 7.89% 
L. plantarum 7.89% 
L. reuteri 6.85% 
L. brevis 6.79% 
L. gasseri 6.05% 
L.  ruminis 6.0% 
L. helveticus 4.15% 
L. johnsonii 4.03% 
L. iners 3.36% 
L. rhamnosus 3.33% 
L. acidophilus 3.25% 
L. casei 3.09% 
L. fermentum 3.01% 
L. amylovorus 2.52% 
L. jensenii 1.67% 
L crispatus 1.39% 
L. ultunensis 1.08% 
L. coleohominis 1.06% 
L. vaginalis 0.99% 
L. antri 0.81% 
L. amylolyticus 0.70% 
L. buchneri 0.52% 
L. hilgardii 0.46% 
L. oris 0.45% 
L. sanfranciscensis 0.05% 
L. sakei 0.05% 
L. agilis 0.02% 
L. pentosus 0.004% 
L. dextrinicus 0.003% 
L. taiwanensis 0.003% 
L. paraplantarum 0.0005% 
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Table 3.4 Average frequency of each Bifidobacterium species out of the total 
Bifidobacterium genus found in the 19 fecal microbiota transplants.  
SPECIES 
PERCENT  OF SPECIES 
IN BIFIDOBACTERIUM 
GROUP 
B. longum 50.05% 
B. animalis 14.52% 
B. bifidum 10.74% 
B. dentium 8.32% 
B. adolescentis 5.44% 
B. breve 2.67% 
B. catenulatum 2.22% 
B. pseudocatenulatum 2.08% 
B. gallicum 1.68% 
B. angulatum 1.20% 
Bifidobacterium sp. 12_1_47bfaa 1.02% 
B. ruminantium 0.02% 
B. asteroides 0.004% 
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Figure 3.5. Frequency of Lactobacillus and Bifidobacterium species from 19 fecal 
microbiota transplants.   
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100% Bifidobacterium sp. 12_1_47BFAA
B. angulatum
B. gallicum
B. pseudocatenulatum
B. catenulatum
B. breve
B. adolescentis
B. dentium
B. bifidum
B. animalis
B. longum
L. ultunensis
L. crispatus
L. jensenii
L. amylovorus
L. fermentum
L. casei
L. acidophilus
L. rhamnosus
L. iners
L. johnsonii
L. helveticus
L.  ruminis
L. gasseri
L. brevis
L. reuteri
L. plantarum
L. paracasei
L. salivarius
L. delbrueckii
44 
 
 
CHAPTER 4:  EVALUATION OF CLOSTRIDIUM DIFFICILE INHIBITION BY 
KEFIR AND SELECT ISOLATE FROM KEFIR, LACTOBACILLUS PARACASEI  
 
ABSTRACT 
 
With Clostridium difficile infection (CDI) causing 30,000 deaths in the United States 
each year, better treatment methods (other than antibiotics) are needed.  Fecal microbiota 
transplants have been one method to emerge in the early 2000s, however it is considered an 
investigational therapy.  This has led to research into the area of probiotics as a potential 
treatment method for CDI. The purpose of this study was to evaluate microorganisms found 
in kefir, for effectiveness against C. difficile. The kefir and the different kefir components 
(cell-free supernatant, cell lysate, fat) inhibition capabilities were tested against C. difficile.  
It was found that neither the different components nor the entire kefir matrix showed any 
inhibition against C. difficile. However, a Lactobacillus paracasei isolate was found to not 
only grow alongside C. difficile, but to have resistance against the antibiotic vancomycin, 
making it a potential candidate for competitive inhibition against C. difficile.  L. paracasei 
showed little inhibition when inoculated at the same population concentration as the C. 
difficile and also did not significantly inhibit C. difficile growth when a one log population 
(CFU/ml) difference was used. 
 
INTRODUCTION 
With the increase in Clostridium difficile infections (CDI), new methods of treatment 
are needed.  Fecal microbiota transplants (FMTs) are starting to replace the traditional 
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antibiotic treatments.  FMTs are fecal microbiota from healthy human donors that are used to 
treat patients with CDI.  Each fecal donations is highly screened for unwanted pathogens and 
viruses and are thought to help “re-inoculate” the CDI patient intestinal tract, with beneficial 
bacteria (Bakken et al. 2011; Shankar et al. 2014).  However, since FMTs are still 
investigational and not always an option for CDI patients, much research has turned to 
probiotics as a potential treatment method for CDI (Patel et al. 2013; Bakken 2014).  A 
disruption in the native gut microbiota allow for spores of C. difficile to start germinating in 
the gut; it is postulated that probiotics can help re-populate the gut and protect the patient 
through their several known inhibitory mechanisms (Plummer et al. 2004).   
Two main probiotics genera, Lactobacillus and Bifidobacterium, have been utilized in 
several CDI clinical studies.  Both Gao et al. (2010) and Hickson et al. (2007) found a 
decrease in C. difficile-associated diarrhea (CDAD) when patients were given a probiotic 
supplement along with antibiotics.  Bakken (2014) utilized a Lifeway® kefir regimen with a 
staggered and tapered antibiotic withdraw (STAW) treatment.  A STAW treatment simply 
means that the dose of antibiotics is decreased over time as well as given less times per day.  
In this study, Bakken found a significant improvement in CDI symptoms along with a 
decreased risk of recurrent CDI.  Kefir, a fermented milk beverage, contains a diverse 
collection of potentially probiotic bacteria.  Due to the high bacterial diversity in kefir, it is 
hypothesis that the bacteria are able to “re-inoculate” the gut, similar to FMTs, and through 
either production of antimicrobials (bacteriocins or short-chain fatty acids) or competitive 
exclusion, inhibit C. difficile germination and growth (Lee & Salaminien 2009; Bakken 
2014).  In another study done by Ambalam et al. (2015), four probiotics strains, which are 
also found in Lifeway® kefir (L. paracasei, L. plantarum, B. breve and B. animalis), were 
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used in in vitro competitive inhibition tests against C. difficile.  In this study, these probiotics 
were found to inhibit C. difficile growth.  This suggests that some (or all) of these probiotics 
may be potentially beneficial in treating CDI.   
Although several meta-analysis studies of clinical studies have suggested that 
probiotics tend to be favored over the control when used to treat CDI, the studies are limited 
and contain mixed results (Johnston et al. 2012).  Limited research has been done to identify 
the mechanisms probiotics use to enable treatment of CDI patients with success.   
Many probiotics are known to produce different types of organic acids and 
antimicrobials, such as butyrate, lactic acid, acetate and bacteriocins (Lee & Salaminien 
2009; Fijan 2016; Spinler et al. 2016).  These compounds would be present in the cell-free 
supernatant of the kefir product. The objective of this research was to investigate the ability 
of kefir, its cell-free components, and individual kefir bacteria to inhibit C. difficile growth 
either from production of antimicrobial compounds or competitive inhibition. 
 
MATERIALS AND METHODS 
Kefir Cell-Free Supernatant Extraction. 
Commercial Lifeway® kefir, purchased from local grocery stores, was centrifuged at 
15,000 x g at 4 °C for 15 minutes in 50 ml sterile centrifuge tubes.  The supernatant was 
decanted after centrifugation and was filtered through 0.8 µm Millipore filters.  Kefir 
Supernatant, cell lysate and fat separation were used in zone of inhibition tests. The fat 
portion was separated by adding 5% polyethylene glycol (FisherChemicals, NJ) to the fat and 
cell lysate sections and centrifuging again at 10,000 x g for 15 minutes.  The cell lysate was 
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decanted after centrifugation, leaving the fat section.  All kefir components were stored at -80 
C until use.  
 
Isolation of and identification of Lactobacillus paracasei from Kefir 
 Isolation of Lactobacillus paracasei was done using cycloserine-cefoxitin-fructose 
agar with sodium taurocholate (TCCFA) (Clostridium difficile agar, BioWorld, Ohio; C. 
difficile supplements, Thermo Scientific; Bovine Blood Defibrinated, Lampire® Bilogical 
Lab, PA).  500ul of kefir was added to 10ml of Brain-Heart Infused (BHI) broth 
(FisherScientific) and vortex.  This solution was streaked on TCCFA plates to obtain an 
isolated colony and incubated in an anaerobic chamber for 48 hours.  One colony from 
streak-plate was added to new BHI broth and incubated in anaerobic chamber for 48 ours.  
After incubation, 500ul was spread onto TCCFA plates and taken to the Iowa State VetMed 
Diagnostic lab (Ames, IA)  for Matrix-assisted laser desorption/ionization identification.  
100ul of L. paracasei broth culture was added to 500ul of glycerol to make glycerol-stock 
and stored at -80 C. 
Zone of inhibition studies 
Pure C. difficile glycerol stock cultures (isolated at ISU VetMed) were used.  Each 
strain was grown up to 108 CFU/ml by first swabbing the pure culture onto TCCFA plates.  
Isolated colonies were added to 10ml Brain-Heart Infused (BHI) broth (FisherScientific) and 
incubated in anaerobic chamber for 12 hours.  The disk diffusion agar overlay method, as 
described in Xia et al. (2012) was used with modifications.  In brief, overnight pure cultures 
(108 CFU/ml) of C. difficile strains were used to create lawns on solid agar plates, grown in 
BHI broth.  Individual C. difficile strains were used to evaluate various levels of virulence.  
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Strains included Ribotype 027/Toxino Type III/NAP 1 (hyper-virulent), Ribotype 020, 
Ribotype 012, Ribotype 002, Ribotype 001, Ribotype 056, Ribotype 126 and Ribotype 010 
(negative toxin production).  Pour plates were made with cycloserine-cefoxitin-fructose agar 
with sodium taurocholate (TCCFA) (Clostridium difficile agar, BioWorld, Ohio; C. difficile 
supplements, Thermo Scientific; Bovine Blood Defibrinated, Lampire® Bilogical Lab, PA) 
and allowed to cool/harden. A 200ul culture suspension of C. difficile was spread onto to 
each respective plate.   
For kefir component (cell-free supernatant, cell lysate, fat) or full kefir (no 
separation), drops (10-100ul) of each sample along with vancomycin and BHI were added on 
top the seeded agar overlay, in four separate quadrants of the plate. The plates were inverted 
and incubated anaerobically in an anaerobic chamber overnight at 37C. Vancomycin was 
used as positive control, and BHI was used as negative control.  Growth was observed after 
48 hours and each separation and strain was done in duplicate. 
In vitro competitive growth assay 
 Competitive inhibition properties of Lactobacillus paracasei against C. difficile was 
measured through in vitro competitive growth assay following the method of Cornick et al 
2017, with some modifications.  In short, three strains of C. difficile (Ribotype 027/Toxino 
Type III/NAP 1 (hyper-virulent), Ribotype 002, and Ribotype 020) and the L. paracasei 
strain (isolated from kefir), were grow separately overnight in BHI broth in an anaerobic 
chamber to create the stock culture of vegetative cells.  BHI broth was used to obtain 
vegetative C. difficile cells and promote their growth to prevent sporulation.  L. paracasei 
(1000ul) was added to each competitive inhibition BHI broth and its control.  Individually 
10ul of each C. difficile strain (in duplicate) was added to the competitive inhibition broth 
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(Table 4.3) and its control BHI broth.  Serial dilutions were done of each stock culture to 
determine initial populations.  After 48 hour incubation, plate counts were done to determine 
colony-forming units per milliliter (CFU/mL).  Competitive inhibitions and controls were 
checked after 24 hours.  Serial dilutions were performed again, along with plate counts, after 
48 hours.  A t-test was used to determine if there was any significant difference between the 
C. difficile grown with L. paracasei and on its own, using JMP (JMP®, Version Pro 12. SAS 
Institute Inc., Cary, NC, 1989-2007). 
 
RESULTS AND DISCUSSION 
Lifeway® kefir has been shown to have a possible benefit to patients with 
Clostridium difficile infection (CDI) (Bakken 2014), but no mechanism has been confirmed.  
Because of this, Lifeway® kefir and kefir components (cell-free supernatant, fat, and cell 
lysate) were used in zone of inhibition tests against different C. difficile strains.  Each 
component (cell-free supernatant, fat, and cell lysate) was used in the zone of inhibition test 
against the C. difficile strain, Ribotype 027/Toxino Type III/NAP 1 human hyper-virulent 
strain.  This strain was used because there are several hundred different pathogenic human C. 
difficile strains, each which produces different amounts of the toxins (toxins A & toxin B).  
This hyper-virulent strain produces higher amounts of both toxins and tends to be hard to 
treat in patients, thus it was used as the first step in investigating kefir’s potential inhibition 
capabilities.  
For all components of the kefir, no inhibition zones were found (Table 4.1), thus 
demonstrating that cell-free supernatant, cell lysate and fat from commercial Lifeway® kefir 
may not contain inhibitory compounds that prevent growth of C. difficile Ribotype 027.  
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Another hypothesis is that in the Lifeway® kefir, the antimicrobials and organic acids were 
not present in high enough concentrations to inhibit C. difficile Ribotype 027.  Further 
investigations to identify if bacteriocins and short-chain fatty acids are present in Lifeway® 
kefir, and to test at which concentrations such compounds could inhibit C. difficile, would 
help answer this question.   
Since no inhibition was found from the separated components, the entire kefir matrix 
(no separation) was investigated with the zone of inhibition test.  Since there are several 
hundred different human C. difficile strains with different toxin production and resistances, a 
selection of nine different strains (Table 4.2) were utilized in zone of inhibition tests to 
evaluate differences between C. difficile strains, in kefir’s ability to inhibit its growth.  
Unfortunately, the kefir did not show any inhibitory effect on the nine different C. difficile 
strains.  This was not expected since kefir was shown to be an effective supplement for CDI 
patients in the study by Bakken (2014).  Again, this result may have been because of low 
concentrations of the potentially beneficial microorganisms or inhibitory compounds in the 
kefir.  In addition to this, the kefir microorganisms may inhibit C. difficile through 
competitive exclusion, which was not tested through the zone of inhibition test.  To test this, 
a competitive inhibition test using just the isolated probiotics strains from kefir, would be 
needed; this is what was done next.   
Through the zone of inhibition study, an unknown bacteria from the kefir was found 
to grow alongside C. difficile.  The fact that it grew alongside C. difficile means that it was 
resistant to the antibiotic, Vancomycin.  After isolation and Matrix-assisted laser 
desorption/ionization (MALDI) identification test from the ISU VetMed Diagnostic lab, the 
microorganism was identified as Lactobacillus paracasei.  The concentration of L. paracasei, 
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determined in two lots of Lifeway® kefir, was 109 CFU/mL.  Because L. paracasei was 
found to grow on the same selective C. difficile agar with C. difficile, it was hypothesized 
that L. paracasei could potentially act as a competitive inhibitor, through competitive 
exclusion, against C. difficile.  Competitive exclusion, a form of competitive inhibition, were 
the probiotic bacteria outcompetes the pathogenic bacteria for bacterial adhesion site (in 
intestine or on media) or outcompetes for similar nutrients.  Because L. paracasei was found 
to grow on a similar selective media agar as C. difficile, it was hypothesized that it could 
inhibit C. difficile through competitive exclusion.  Along with this, L. paracasei in 
combination with other probiotics, was found to inhibit C. difficile in a similar study by 
Ambalam et al. (2015).  In this study, the probiotics L. paracasei, L. plantarum, B. breve and 
B. animalis, were evaluated as a group and if they used cross-feeding in the co-cultures to 
enhance their inhibition against C. difficile.  Cross-feeding is common amongst several 
probiotic species; it is the growth enhancement of probiotics by the byproducts of other 
probiotic bacteria.  Ambalam et al (2015) found that L. paracasei, L. plantarum, B. breve and 
B. animalis used together did show inhibition C. difficile growth. 
To investigate further, L. paracasei was used in an in vitro competitive growth assay.  
For this study, a greater population concentration of the L. paracasei was used against a 
smaller population concentration of C. difficile to test if having an increase in the probiotics 
would prevent C. difficile growth.  However, as shown in Table 4.3, L. paracasei did not 
significantly inhibit the growth of any of the three C. difficile strains used (Ribotype 
027/Toxino Type III/NAP 1 (hyper-virulent), Ribotype 002, and Ribotype 020) through 
competitive exclusion.  One hypothesis for this is that not one probiotic is needed to out-
compete C. difficile, but many.  It has been well established that probiotics can stimulated 
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other the growth of other potentially probiotic bacteria, through cross-feeding, by producing 
by-products that are usable as energy; this concept was established with L. paracasei and B. 
breve in Ambalam et al. (2015).   
This hypothesis that a cocktail of potential beneficial bacteria may be appropriate for 
treating CDI is supported by the results found in Chapter 3.  The human gut is made up of a 
diverse amount of beneficial probiotic bacteria and many Lactobacillus and Bifidobacterium 
species were found to be common across 19 healthy donors.  Thus, it could be more 
beneficial to utilize a treatment of a large diversity (one similar to a healthy FMT donor) as a 
treatment for CDI, not just a few select ones. 
 
CONCLUSIONS 
 Using Lifeway® kefir (and its components) in zone of inhibition test was 
unsuccessful at inhibiting C. difficile.  Lactobacillus paracasei, a probiotic found in kefir, 
was identified as a potential competitive exclusion bacteria since it could grow on similar 
selective nutrient media and was resistant to one of the main antibiotics used to treat CDI, 
vancomycin.  But in the competitive inhibition study, L. paracasei did not significantly 
decrease C. difficile growth, even when present in a higher cell concentration.  Further 
research is warranted to investigate if L. paracasei, when combined with additional select 
bacteria, could inhibit C. difficile.   
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Table 4.1.  Zone of inhibition test of kefir components against C. difficile Ribotype 
027/Toxino type III/Nap 1 human hyper-virulent strain 
Kefir Component 
Vancomycin 
(10ul) 
BHI (10ul) 
Fat (100ul) No inhibition inhibition No inhibition 
Cell Lysate (10ul) No inhibition inhibition No inhibition 
Combine (Fat & 
Cell-Lysate) 
(100ul) 
No inhibition inhibition No inhibition 
Inhibition is defined as any clearing, or zone of inhibition of C. difficile growth 
  
 
  
 
Table 4.2.  Summary of zone of inhibition tests of kefir against 9 human virulent C. difficile strains.   
 
C. difficile Strain Kefir  BHI (negative control)  
Vancomycin (positive 
control) 
Ribotype 027/Toxino Type III/NAP 1  
hyper-virulent strain2 
No inhibition  No inhibition Inhibition 
Ribotype 030/double positive1,2 No inhibition No inhibition Inhibition 
Ribotype 012/double positive1,2 No inhibition No inhibition Inhibition 
Ribotype 0022,3 No inhibition No inhibition Inhibition 
Ribotype 020/double positive1,2 No inhibition No inhibition Inhibition 
Ribotype 0012,3 No inhibition No inhibition Inhibition 
Ribotype 056/double positive1,2 No inhibition No inhibition  Inhibition 
Ribotype 126/double positive1,2 No inhibition No inhibition Inhibition 
Ribotype 010/Double Negative3,4 No inhibition No inhibition Inhibition 
1 double positive means produces both toxin 
A & B 
2 All C. difficile strains are human virulent 
strains 
3 toxin production is unknown 
4 double negative means no toxins (A & B) are produced 
Each strain done in 4 replications 
Inhibition is in regards to C. difficile growth 
5
8
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Table 4.3. Competitive inhibition of Lactobacillus paracasei against C. difficile strains.   
Competitive means grown with L. paracasei, control is without.  No inhibition was found to 
be significant between strains competitive group and control. 
 
C. difficile strain 
Competitive 
(Average log 
CFU/ml) 
Control 
(Average log 
CFU/ml) 
P-value 
Ribotype 0022,3 7.9 7.3 p > 0.05 
Ribotype 020/double 
positive1,2 
8.1 7.9 p > 0.05 
Ribotype 027/Toxino 
Type III/NAP 1 hyper-
virulent strain2 
7.7 7.7 p > 0.05 
1 double positive means produces both toxin A & B 
2 human virulent strains 
3 toxin production is unknown 
60 
 
 
CHAPTER 5: GENERAL CONCLUSION 
Through this study, it was established that fecal microbiota transplant material from 
19 healthy humans were primarily composed of Bacteroidetes and Firmicutes bacteria.  
Faecalibacterium prausnitzii made up one of the largest species populations present across 
the 19 FMT donors; the microorganism has been established to produce high amounts of 
butyrate and anti-inflammatory compounds.  However, very few studies have investigated if 
this microorganism is effective against C. difficile and if it could potential help treat CDI 
patients. 
The WGS of the 19 FMTs also displayed that a healthy microbiota is made up of 
several different Lactobacillus and Bifidobacterium species.  Many of these potentially 
probiotic bacteria species are also present in kefir products.  However, Lifeway® kefir, 
which was effective in helping CDI patients recover one previous study, was found to not 
inhibit several different C. difficile strains.   
Lactobacillus paracasei, which was isolated from Lifeway® kefir, showed some 
potential to act as a competitive inhibitor through competitive exclusion, since it was 
resistant to vancomycin and utilized similar nutrients to C. difficile. Yet it was found to not 
significantly decrease the growth of three strains of C. difficile in the competitive inhibition 
studies.   
Overall, through the WGS of FMTs and kefir inhibition tests, the present research 
suggests that many different potentially probiotic species need to be investigated, as cocktails 
for their ability to inhibit C. difficile growth.  With such studies, we will gain a better 
understanding of the mechanisms of action and potential treatment for CDI. 
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CHAPTER 6: FUTURE RESEARCH 
 
 Probiotics have shown some success in treating CDI patient in clinical trials, however 
more research is needed.  WGS has displayed that several different probiotic bacteria species 
are present cross many healthy donors, suggesting that it may take more than one or two to 
help treat CDI. To test this hypothesis, future research in the area of probiotics as a treatment 
method for CDI, needs to focus on several probiotic bacteria species, such as Lactobacillus 
and Bifidobacterium, they are commonly present in a healthy human GI tract instead of just 
looking at one or two. Understanding how these gut probiotic bacteria function could lead to 
better understanding into the type of probiotics need to treat CDI patients.   
Research has shown that dairy products such as kefir, can be beneficial in treating 
CDI; however more research is needed in investigating the types of antimicrobial or short-
chain fatty acids produced by the probiotics as well as establishing the concentration that 
would be need to potential inhibit C. difficile. In addition, more research focusing on 
Lactobacillus paracasei, the probiotic isolated from kefir, could provide more insight into if 
it can be beneficial in treating CDI.  In other studies, it was found to have an increased 
growth when grown with other Lactobacillus and Bifidobacterium species; further suggesting 
that a cocktail of several different probiotics could increase inhibition of C. difficile.  
Along with this, Faecalibacterium prausnitzii, which a major gut microbiota (making 
up 15% of gut microbiota), has been established as a bacteria helpful in treating IBS patients 
and produces butyrate and anti-inflammatories.  Research is very limited if F. prausnitzii is 
present in CDI patients and if it could be utilized to treat CDI.  As technologies improve in 
the area of genomic sequencing and culturing, our understanding of how the gut microbiota 
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works and promotes human health, with only increase our ability to treat intestinal disease 
and infections, such as CDI. 
 
